Prenetics CFO of IM8 Buys $497,700 of Stock in Open Market
PRE has more than doubled off its 52-week low of $7.18 on elevated volume (2.3× avg).
Summary
CFO of IM8 (US) LLC Brian J Rosin bought $497,700 of Prenetics stock in the open market on August 24-25, 2026, at $21.19-$22.80 per share.
Key Events · Ownership and Investor Activity · PRE
-
CFO of IM8 Buys $497,700 in Open Market
Brian J Rosin, CFO of IM8 (US) LLC, acquired 23,100 Class A ordinary shares for $497,700 in two open-market purchases on August 24-25, 2026, at $21.19-$22.80 per share.
-
Cluster of Insider Accumulation
This purchase follows CEO Danny Yeung's $502K open-market buy disclosed on August 25, 2026, creating a two-insider accumulation signal within one week.
-
Post-Transaction Holdings
Rosin now directly holds 23,100 shares, representing his entire reported position in Prenetics.
-
Context: Strong IM8 Momentum
The purchase comes after IM8 secured a $1 billion non-dilutive financing facility from General Catalyst and raised FY2026 revenue guidance to $220-230M.
Analysis · PRE · Life Sciences
Brian J Rosin, CFO of IM8 (US) LLC, bought 23,100 shares for $497,700 on August 24-25 at $21.19-$22.80 per share. This follows CEO Danny Yeung's $502K open-market purchase disclosed just one day earlier, creating a cluster of insider accumulation at the top of the company. The purchase is real money out of pocket, not an option exercise, and comes amid strong IM8 brand momentum and a $1 billion non-dilutive financing facility.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRE was trading at $22.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $398.6M. The 52-week trading range was $7.18 to $23.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.